Nasal vs Sublingual Ketamine

Reviewed and authored by Dr. David Mahjoubi, MD — Board-Certified Anesthesiologist, President of the American Board of Ketamine Physicians (ABKP), Founder of NutraBrain Clinic. Practicing ketamine medicine since 2014. Author of The Art & Science of Ketamine Medicine.

If you’ve been prescribed ketamine for depression, anxiety, PTSD, or chronic pain, you’ve probably been offered a choice between forms: a nasal spray or a sublingual troche/tablet. Both work. Both are clinically validated. They feel different and produce slightly different experiences — and choosing between them comes down to a few specific factors.

A quick overview of the two routes

Intranasal ketamine is a liquid solution sprayed into the nostrils, absorbing through the nasal mucosa into the bloodstream and reaching the brain within minutes. Pharmacy-compounded intranasal ketamine is delivered in calibrated single-spray doses (typically 50–75 mg per session for adults).

Sublingual ketamine comes in two formats: troches (slow-dissolving lozenges held under the tongue 10–20 minutes) and rapidly dissolving tablets (RDTs, dissolve in 1–2 minutes). The drug absorbs through the vascular network under the tongue, bypassing some first-pass liver metabolism. Doses typically range 50–200 mg per session.

Both are sub-anesthetic — far below surgical anesthesia doses — and both are appropriate for at-home use under physician supervision.

Pharmacokinetics — speed, peak, duration

Property	Intranasal	Sublingual Troche	Sublingual RDT
Onset of effects	5–10 min	15–25 min	10–15 min
Peak effect	20–40 min	45–60 min	30–45 min
Duration of dissociation	30–60 min	60–90 min	45–75 min
Bioavailability (approx.)	25–50%	20–30%	20–30%
Total session length	~60 min	~90–120 min	~75–90 min

Intranasal is fast on and fast off. Patients who want a more contained session or prefer not to dwell in the dissociative state often prefer it. Bioavailability is the highest of any non-IV route. Sublingual troches produce a longer, gentler curve. Many patients describe this as more “therapeutic” — more time to sit with the experience, more room for emotional processing. Rapidly dissolving tablets sit between the two.

Patient experience differences

Intranasal: clear shift within 10 minutes. Some patients describe a fast “rise.” Side effects (mild nausea, brief bitter taste, blocked nasal sensation) usually short-lived.

Sublingual: slower, gradual build. Patients often notice nothing for 10–15 minutes, then describe a smooth transition into the therapeutic state. The trade-off is the hold time — patients who struggle to keep the medication under the tongue without swallowing lose dose to the GI tract, where bioavailability is much lower (~5%).

Subjective ratings from my patients generally split roughly 50/50 between routes. Almost no one says one is “better” — they say one is better for them.

Which form for which condition

Treatment-resistant depression and anxiety: Either route is appropriate. Many patients start with troches for the longer therapeutic arc and switch to nasal spray for maintenance once they understand the experience.

PTSD: Sublingual troches are often preferred. The longer therapeutic window provides more time for trauma processing, particularly when paired with structured psychotherapy between sessions.

OCD and persistent ruminative thinking: Either route. Some patients respond better to the faster, sharper onset of nasal spray for breaking intrusive thought loops.

Chronic pain (neuropathic, fibromyalgia, CRPS): Sublingual troches at lower doses taken more frequently tend to outperform high-dose dissociative sessions for pain. Sub-perceptual dosing often works better for pain.

Microdosing protocols: Sublingual troches and RDTs allow the finest dose titration. Microdosing via nasal spray is feasible but less precise.

Patients with nasal congestion, sinus problems, or deviated septum: Sublingual only.

Patients who dislike or struggle with the sublingual hold requirement: Nasal spray.

What about IV infusions?

IV delivers 100% bioavailability and a very controlled blood level, which is why it remains the gold standard for severe treatment-resistant depression and acute suicidal crisis. However, IV runs $400–$800 per session at most clinics, requires multiple sessions per week initially, and involves transportation and clinic logistics. Therapeutic outcomes from at-home intranasal and sublingual ketamine are comparable to IV for the majority of patients when paired with consistent physician oversight.

The exclusive NutraBrain option — ketamine + oxytocin nasal spray

NutraBrain offers a compounded nasal spray combining ketamine with oxytocin (the bonding hormone). Not available anywhere else. Patients consistently describe it as transformative for emotional connection, intimacy, and breaking through emotional numbness — particularly in the context of relationship issues, attachment trauma, and post-PTSD recovery.

Frequently asked questions

Making the choice

Three questions I ask: (1) Any sinus or nasal issues? If yes → sublingual only. (2) Prefer a faster, sharper experience or a slower, more contemplative one? Faster → nasal. Slower → sublingual. (3) Primary condition? PTSD and chronic pain → typically sublingual. Depression and anxiety → either works.

If you’re not sure, take the 20-second quiz or schedule a consult.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Ketamine therapy is a prescription treatment and should only be undertaken under physician supervision. Individual outcomes vary. Ketamine use for mental health and chronic pain conditions outside of FDA-approved esketamine (Spravato) is considered off-label. Speak with a qualified physician about whether ketamine therapy is appropriate for you.

Last reviewed: June 2026